Identification of bacterial agents and antimicrobial susceptibility related to urinary tract infection in patients treated at the Mount Sinai laboratory during the 2023 period

Abstract

In recent decades, there has been a change in the clinical course of urinary tract infection as a result of the introduction of antibiotic treatment, improved diagnostic methods, and access to healthcare. The overall objective was to evaluate the bacterial agents and antimicrobial susceptibility related to urinary tract infections in patients treated at the Monte Sinaí laboratory in 2023, where urinary tract infection is considered the most common pathology associated with pregnancy. The methodology used was cross-sectional, non-experimental, and a retrospective minimal-risk study. The results showed that females predominated, finding that the highest bacterial etiological prevalence was found in Escherichia coli, which is the most frequent microbial agent of antimicrobial susceptibility, concluding that antimicrobial susceptibility is a test with significant clinical utility, since by applying it we can identify the appropriate treatment for the type of bacteria isolated, determining the antibiotic to which it is resistant, sensitive, or intermediate, finding that most of the isolated bacteria were resistant to the nalidixic acid, ampicillin sulbactam, and rifampicin groups.